Extracorporeal treatments for isoniazid poisoning : Systematic review and recommendations from the EXTRIP workgroup
© 2021 Pharmacotherapy Publications, Inc..
Isoniazid toxicity from self-poisoning or dosing errors remains common in regions of the world where tuberculosis is prevalent. Although the treatment of isoniazid poisoning is centered on supportive care and pyridoxine administration, extracorporeal treatments (ECTRs), such as hemodialysis, have been advocated to enhance elimination of isoniazid. No systematic reviews or evidence-based recommendations currently exist on the benefit of ECTRs for isoniazid poisoning. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup systematically collected and rated the available evidence on the effect of and indications for ECTRs in cases of isoniazid poisoning. We conducted a systematic review of the literature, screened studies, extracted data on study characteristics, outcomes, and measurement characteristics, summarized findings, and formulated recommendations following published EXTRIP methods. Forty-three studies (two animal studies, 34 patient reports or patient series, and seven pharmacokinetic studies) met inclusion criteria. Toxicokinetic or pharmacokinetic analysis was available for 60 patients, most treated with hemodialysis (n = 38). The workgroup assessed isoniazid as "Moderately Dialyzable" by hemodialysis for patients with normal kidney function (quality of evidence = C) and "Dialyzable" by hemodialysis for patients with impaired kidney function (quality of evidence = A). Clinical data for ECTR in isoniazid poisoning were available for 40 patients. Mortality of the cohort was 12.5%. Historical controls who received modern standard care including appropriately dosed pyridoxine generally had excellent outcomes. No benefit could be extrapolated from ECTR, although there was evidence of added costs and harms related to the double lumen catheter insertion, the extracorporeal procedure itself, and the extracorporeal removal of pyridoxine. The EXTRIP workgroup suggests against performing ECTR in addition to standard care (weak recommendation, very low quality of evidence) in patients with isoniazid poisoning. If standard dose pyridoxine cannot be administered, we suggest performing ECTR only in patients with seizures refractory to GABAA receptor agonists (weak recommendation, very low quality of evidence).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 41(2021), 5 vom: 03. Mai, Seite 463-478 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mowry, James B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.12.2021 Date Revised 27.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/phar.2519 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322177243 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322177243 | ||
| 003 | DE-627 | ||
| 005 | 20231225181459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/phar.2519 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM322177243 | ||
| 035 | |a (NLM)33660266 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mowry, James B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extracorporeal treatments for isoniazid poisoning |b Systematic review and recommendations from the EXTRIP workgroup |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2021 | ||
| 500 | |a Date Revised 27.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Pharmacotherapy Publications, Inc. | ||
| 520 | |a Isoniazid toxicity from self-poisoning or dosing errors remains common in regions of the world where tuberculosis is prevalent. Although the treatment of isoniazid poisoning is centered on supportive care and pyridoxine administration, extracorporeal treatments (ECTRs), such as hemodialysis, have been advocated to enhance elimination of isoniazid. No systematic reviews or evidence-based recommendations currently exist on the benefit of ECTRs for isoniazid poisoning. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup systematically collected and rated the available evidence on the effect of and indications for ECTRs in cases of isoniazid poisoning. We conducted a systematic review of the literature, screened studies, extracted data on study characteristics, outcomes, and measurement characteristics, summarized findings, and formulated recommendations following published EXTRIP methods. Forty-three studies (two animal studies, 34 patient reports or patient series, and seven pharmacokinetic studies) met inclusion criteria. Toxicokinetic or pharmacokinetic analysis was available for 60 patients, most treated with hemodialysis (n = 38). The workgroup assessed isoniazid as "Moderately Dialyzable" by hemodialysis for patients with normal kidney function (quality of evidence = C) and "Dialyzable" by hemodialysis for patients with impaired kidney function (quality of evidence = A). Clinical data for ECTR in isoniazid poisoning were available for 40 patients. Mortality of the cohort was 12.5%. Historical controls who received modern standard care including appropriately dosed pyridoxine generally had excellent outcomes. No benefit could be extrapolated from ECTR, although there was evidence of added costs and harms related to the double lumen catheter insertion, the extracorporeal procedure itself, and the extracorporeal removal of pyridoxine. The EXTRIP workgroup suggests against performing ECTR in addition to standard care (weak recommendation, very low quality of evidence) in patients with isoniazid poisoning. If standard dose pyridoxine cannot be administered, we suggest performing ECTR only in patients with seizures refractory to GABAA receptor agonists (weak recommendation, very low quality of evidence) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a EXTRIP | |
| 650 | 4 | |a consensus recommendations | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a dialyzability | |
| 650 | 4 | |a extracorporeal treatment | |
| 650 | 4 | |a isoniazid | |
| 650 | 4 | |a poisoning | |
| 650 | 4 | |a systematic review | |
| 650 | 7 | |a Pyridoxine |2 NLM | |
| 650 | 7 | |a KV2JZ1BI6Z |2 NLM | |
| 650 | 7 | |a Isoniazid |2 NLM | |
| 650 | 7 | |a V83O1VOZ8L |2 NLM | |
| 700 | 1 | |a Shepherd, Greene |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffman, Robert S |e verfasserin |4 aut | |
| 700 | 1 | |a Lavergne, Valery |e verfasserin |4 aut | |
| 700 | 1 | |a Gosselin, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Nolin, Thomas D |e verfasserin |4 aut | |
| 700 | 1 | |a Vijayan, Anitha |e verfasserin |4 aut | |
| 700 | 1 | |a Kielstein, Jan T |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Darren M |e verfasserin |4 aut | |
| 700 | 1 | |a Ghannoum, Marc |e verfasserin |4 aut | |
| 700 | 0 | |a Extracorporeal Treatments in Poisoning workgroup |e verfasserin |4 aut | |
| 700 | 1 | |a Alhatali, Badria |e investigator |4 oth | |
| 700 | 1 | |a Anseeuw, Kurt |e investigator |4 oth | |
| 700 | 1 | |a Bird, Steven |e investigator |4 oth | |
| 700 | 1 | |a Berling, Ingrid |e investigator |4 oth | |
| 700 | 1 | |a Bouchard, Josée |e investigator |4 oth | |
| 700 | 1 | |a Bunchman, Timothy E |e investigator |4 oth | |
| 700 | 1 | |a Calello, Diane P |e investigator |4 oth | |
| 700 | 1 | |a Chin, Paul K |e investigator |4 oth | |
| 700 | 1 | |a Doi, Kent |e investigator |4 oth | |
| 700 | 1 | |a Galvao, Tais |e investigator |4 oth | |
| 700 | 1 | |a Goldfarb, David S |e investigator |4 oth | |
| 700 | 1 | |a Hassanian, Hossein |e investigator |4 oth | |
| 700 | 1 | |a Hoegberg, Lotte C |e investigator |4 oth | |
| 700 | 1 | |a Kallab, Siba |e investigator |4 oth | |
| 700 | 1 | |a Kebede, Sofia |e investigator |4 oth | |
| 700 | 1 | |a Lewington, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Li, Yi |e investigator |4 oth | |
| 700 | 1 | |a Macedo, Etienne M |e investigator |4 oth | |
| 700 | 1 | |a MacLaren, Rob |e investigator |4 oth | |
| 700 | 1 | |a Megarbane, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Ostermann, Marlies E |e investigator |4 oth | |
| 700 | 1 | |a Peng, Ai |e investigator |4 oth | |
| 700 | 1 | |a Roy, Jean-Philippe |e investigator |4 oth | |
| 700 | 1 | |a Walsh, Steven J |e investigator |4 oth | |
| 700 | 1 | |a Wong, Anselm |e investigator |4 oth | |
| 700 | 1 | |a Wood, David M |e investigator |4 oth | |
| 700 | 1 | |a Yates, Christopher |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 41(2021), 5 vom: 03. Mai, Seite 463-478 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:5 |g day:03 |g month:05 |g pages:463-478 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/phar.2519 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 5 |b 03 |c 05 |h 463-478 | ||